Quick Answer
Lexaria Bioscience Corp. reported R&D Expense of $8.24 million for fiscal year 2025.
Lexaria Bioscience Corp. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $8.24M | +249.0% |
| 2024 | $2.36M | -35.6% |
| 2023 | $3.67M | +99.0% |
| 2022 | $1.84M | +45.9% |
| 2021 | $1.26M | +226.3% |
| 2020 | $387.1K | -30.3% |
| 2019 | $555.7K | +12.8% |
| 2018 | $492.9K | +809.6% |
| 2017 | $54.2K | +500.5% |
| 2016 | $9.0K | -93.8% |
| 2015 | $146.5K | — |
| 2014 | $0.00 | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| November 30, 2025 | $671.3K | -65.6% | -75.3% |
| May 31, 2025 | $2.72M | +374.2% | +61.2% |
| February 28, 2025 | $1.69M | +585.9% | -13.7% |
| November 30, 2024 | $1.95M | +240.0% | +240.8% |
| May 31, 2024 | $573.1K | -65.1% | +133.2% |
| February 29, 2024 | $245.8K | -64.7% | -57.2% |
| November 30, 2023 | $574.5K | -30.7% | -65.0% |
| May 31, 2023 | $1.64M | +118.1% | +135.7% |
- Lexaria Bioscience Corp. showed an increase of +249.0% in R&D Expense compared to the prior fiscal year.
- The most recent figure is from Lexaria Bioscience Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 28, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: